Parecoxib, a selective cyclooxygenase-2 (COX-2) inhibitor administered for 18 days following lithium-pilocarpine induced SE is neuroprotective (but not anti-epileptogenic) (Polascheck et al., 2010), and Celecoxib reduces neuronal injury and microglia activation when administered one day after lithium-pilocarpine induced status epilepticus (Jung et al., 2006). This evidence concerns the gene PTGS2 and status epilepticus.